CBCharles BoucherMD, PhDSlidesetHIVChinese HIV Clinical Forum 2018Resistance Characteristics of different Integrase Inhibitors- Charles Boucher, MD, PhDView Slideset
SlidesetHIVChinese HIV Clinical Forum 2018HIV integrase Inhibitors: A novel mechanisms of action- Dr. H. WuView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2018What is the Pharmacological support for reduced drug regimens?- Esteban Ribera, MD, PhDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2018Integrating novel delivery systems/novel drugs- Maria Luisa Montes, MD, PhDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2018Clinical Case presentation- Antonio Antela, MDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2018Interstitial pneumonia by triple viral co-infection in a CDC C2 HIV- infected patient- Carme BrackeView Slideset
JAJose ArribasMDSlidesetHIVSpanish HIV Clinical Forum 2018Optimizing Clinical Care- José Arribas, MDView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2018Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study- Jésus TroyaView Slideset
SlidesetHIVSpanish HIV Clinical Forum 2018State of the ART: Integrase Inhibitors Clinical Data- Juan Berenguer, MDView Slideset
JMLJosep M. LlibreMD, PhDSlidesetHIVSpanish HIV Clinical Forum 2018What is the Virological support for reduced drug regimens?- Josep Llibre, MD, PhDView Slideset
SlidesetRSVInternational Conference on (Re-) Emerging Infectious Diseases (ICREID) 2018Public private partnership- Marguerite Massinga Loembe, MSc, PhDView Slideset
SlidesetRSVInternational Conference on (Re-) Emerging Infectious Diseases (ICREID) 2018How to manage global coordination/collaborations during an outbreak- Christian Bréchot, MD, PhDView Slideset
